Clinical trial · Interventional
Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy
Simultaneous Integrated Boost (SIB) Technique in the Adjuvant Radiotherapy of Breast Cancer Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Treatment standard has changed
Summary
Brief summary (as posted)
Adjuvant radiotherapy after breast conserving surgery has been shown to improve both local control and overall survival. Dose escalation of the tumor bed by addition of a boost after whole breast radiotherapy reduces the risk of local recurrence in invasive breast cancer. Simultaneous integrated boost (SIB) techniques have been shown to provide more conformal treatment plans than conventional sequential boost, in addition, SIB enables a reduction in the overall treatment time by 1 week compared to conventional boost techniques. The proposed study is aimed at evaluating radiation-induced toxicity in patients treated with breast-conserving surgery in combination with radiotherapy using SIB technique.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Radiotherapy Side Effect | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Simultaneous integrated boost | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Simultaneous integrated boost arm
- interventionNames
- Radiation: Simultaneous integrated boost
Primary outcomes (2)
- measure
- Acute Radiation induced toxicity (grade 2 or higher)
- timeFrame
- Measurement at the last 1 day of radiotherapy
- description
- Toxicity score using Common Terminology for Adverse Events (CTCAE)
- measure
- Acute Radiation induced toxicity (grade 2 or higher)
- timeFrame
- Measurement 3 months after completion of radiotherapy
- description
- Toxicity score using Common Terminology for Adverse Events (CTCAE)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Invasive breast cancer or ductal carcinoma in situ * Breast conserving surgery * Complete tumor resection * Treatment with adjuvant radiotherapy of the breast * Indication for boost Irradiation * Given informed consent Exclusion Criteria: * Incomplete tumor resection * Mastectomy * Distant metastases at diagnosis * Unable to give informed consent
References
Publications (1)
- BACKGROUNDHurkmans CW, Dijckmans I, Reijnen M, van der Leer J, van Vliet-Vroegindeweij C, van der Sangen M. Adaptive radiation therapy for breast IMRT-simultaneously integrated boost: three-year clinical experience. Radiother Oncol. 2012 May;103(2):183-7. doi: 10.1016/j.radonc.2011.12.014. Epub 2012 Jan 24. PMID 22280808